Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07562230

Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds

This multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells (EpiSCs) for repairing difficult-to-heal wounds. Eligible patients are randomized to receive either: (1) the experimental intervention (rapidly constructed EpiSCs-loaded scaffold combined with split-thickness skin graft via one-step or two-step procedure), or (2) control intervention (acellular scaffold combined with split-thickness skin graft). The primary outcome is the complete wound healing rate at 4 weeks post-surgery. Secondary outcomes include wound recurrence, scar quality (VSS/POSAS), functional recovery (sweat test), mortality, amputation rate, and safety profile.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Location status: Recruiting

Location contact

The First Affiliated Hospital of Sun Yat-sen University

CONTACT

[email protected]

87755766-8265

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All-age population

Wounds requiring surgical repair (single area 10-100 cm²): acute wounds (burns, traumatic defects, post-scar resection) OR chronic wounds (diabetic foot ulcers, pressure injuries, vascular ulcers)

Completed wound bed preparation (no necrotic tissue, infection controlled)

Signed informed consent and agreement to use tissue-engineered materials and long-term follow-up

Exclusion criteria

  • History of allergy to allogeneic/xenogeneic tissue-engineered scaffolds or collagen materials

Severe immunosuppression (HIV/AIDS, long-term immunosuppressant use)

Malignant tumors, uncontrolled systemic infection (CRP > 50 mg/L), or organ failure (Child-Pugh Class C)

Mental illness preventing compliance with treatment or follow-up

Pregnant or lactating women

Treatment and study plan

Rapid Tissue-Engineered Skin

Procedure

Autologous split-thickness skin (0.15-0.2 mm) is harvested from the donor site at a donor-to-wound area ratio of 1:20-30. The harvested skin is processed using a specialized cell sorter to isolate autologous epidermal stem cells (EpiSCs) with >93% viability within 30 minutes. The cell suspension is adjusted to a concentration of ≥1×10⁶ cells/mL and loaded onto a tissue-engineered scaffold via spraying or immersion (3-5 minutes). The cell-seeded scaffold is then applied to the wound bed. Depending on wound condition: (1) One-step procedure: scaffold and a split-thickness skin graft (0.15-0.2 mm) are applied simultaneously; (2) Two-step procedure: scaffold is implanted first, followed by split-thickness skin graft at 14±3 days post-primary surgery. Negative pressure wound therapy (-100 to -125 mmHg) is applied as needed.

Traditional Composite Skin Graft

Procedure

The same tissue-engineered scaffold (without cell loading) is used. Autologous split-thickness skin graft (0.15-0.2 mm thickness) is harvested. The acellular scaffold is applied to the debrided wound bed followed by coverage with the split-thickness skin graft. The surgical procedure, postoperative wound care, negative pressure wound therapy (-100 to -125 mmHg when indicated), and follow-up protocol are identical to those in the experimental arm. This comparator represents the current standard of care for composite skin grafting in the participating centers.

Primary outcomes

  1. Complete Wound Healing Rate

    Time frame: At 4 weeks post-surgery

    The percentage of participants achieving complete wound epithelialization (defined as 100% re-epithelialization without drainage or dressing requirements)

Secondary outcomes

  1. Wound Recurrence Rate

    Time frame: 3, 6, 12 months post-surgery

    Incidence of wound recurrence at the healed site

  2. Scar Quality Assessment

    Time frame: 4 weeks, 3, 6, 12 months post-surgery

    Scar quality is assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at 4 weeks, 3, 6, and 12 months post-surgery. The VSS total score ranges from 0 to 13, with higher scores indicating worse scar outcome (assessing vascularity, pigmentation, pliability, and height). The POSAS includes two separate subscales: the Observer Scale (6 items, each scored 1 to 10, total range 6-60) and the Patient Scale (6 items, each scored 1 to 10, total range 6-60). For both POSAS subscales, higher scores represent worse scar outcome.

  3. Functional Recovery

    Time frame: 6, 12 months post-surgery

    Sweat test for assessment of sweat gland regeneration

  4. Mortality Rate

    Time frame: 3, 6, 12 months post-surgery

    All-cause mortality

  5. Amputation Rate

    Time frame: 3, 6, 12 months post-surgery

    Incidence of amputation (for chronic wound patients)

  6. Healing Trajectory

    Time frame: 1, 2, 3 weeks post-surgery

    Wound healing rate at week 1, 2, 3; and time to complete healing

  7. Safety Outcome

    Time frame: From day of surgery through 12 months post-surgery

    Safety outcome is the incidence of postoperative complications (including infection, hematoma, and graft failure), adverse events, and serious adverse events, assessed from the day of surgery through study completion, an average of 12 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Hu Zhicheng

CONTACT

[email protected]

87755766-8265

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University

Other

Registry information

Official study title

Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds: A Multicenter Real-world Study

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.